What people are reporting about VIP for chronic inflammation

There is a particular category of online health community that coalesces around illnesses that mainstream medicine either doesn't recognize or can't adequately treat. The chronic illness forums are different from the biohacker forums, though they sometimes overlap. The biohacker contingent is optimizing; the chronic illness community is often just trying to get through the week. What they share is a reliance on peer knowledge — on the accumulated experience of people who have read the same research papers, tried the same protocols, and reported back with a granularity that clinical trials rarely capture.

VIP — Vasoactive Intestinal Peptide — has a significant presence in several of these communities. The r/CIRS subreddit, the r/MCAS subreddit, various long COVID communities including patient advocacy organizations and Facebook groups, fibromyalgia forums, and the broader chronic fatigue and ME/CFS communities have all generated substantial discussion about VIP over the past several years. What follows is a synthesis of the themes that appear consistently across these discussions.

The most common context in which VIP appears in community reports is the Shoemaker CIRS protocol. People discussing CIRS online — and the CIRS community has built an unusually detailed shared knowledge base, partly because Shoemaker's protocol is sequential and well-documented — tend to approach VIP as a late-stage step rather than a first intervention. The community discourse reflects the protocol's structure: many posters describe years of work before reaching the VIP phase, having already removed themselves from the water-damaged building, completed cholestyramine binding, addressed potential mold colonization, and worked through a series of hormonal and inflammatory markers with a Shoemaker-trained physician.

The sequencing conversation is prominent. Reports of people who tried VIP earlier in the process — before adequate biotoxin removal or before addressing antigen-producing sources — often describe worsening symptoms or no benefit. The community understanding, repeated consistently across posts from different users and different time periods, is that VIP is a late-stage regulatory tool and that using it out of sequence is a common mistake. This represents accumulated community learning from shared adverse experience, and it aligns with the theoretical framework behind the protocol even if the underlying evidence base for that framework is contested.

The intranasal route is the most commonly discussed in CIRS-adjacent posts. Reports describe a gradual taper-up approach — starting at lower doses and increasing over days to weeks — that appears to reduce the incidence of side effects. The most commonly reported side effect in the community is nasal irritation: dryness, mild burning, occasional epistaxis. These are consistently described as manageable and often resolving as the nasal mucosa adapts. A smaller subset of reports describes GI symptoms — nausea, loose stools — particularly at higher doses or on initial introduction. Rare reports mention transient orthostatic symptoms, particularly lightheadedness shortly after administration, which aligns with VIP's known vasodilatory properties.

The dose and frequency conversation runs through virtually every VIP thread. Multiple-times-daily dosing appears to be the norm in the CIRS community — reports range from two to four administrations daily — reflecting VIP's short half-life and the corresponding need for repeated dosing to maintain whatever steady-state effect users report. The exact dosing protocols vary by the prescribing provider's preference and are not standardized in the way that approved pharmaceuticals would be. Several posts note that their specific protocol came from a Shoemaker-trained physician and caution against applying another person's dosing without provider guidance, a notable feature of a community that is often self-taught and protocol-fluent.

The outcomes that CIRS forum members attribute to VIP most frequently cluster around cognitive and neurological symptoms: brain fog lifting, improved word retrieval, better sustained concentration, reduced sensitivity to light and sound. These are among the most debilitating symptoms in CIRS, and they are consistently described as among the first things that improve when VIP is introduced at the right stage of the protocol. Less consistent but present in the reports are descriptions of autonomic symptom improvement — better exercise tolerance, reduced orthostatic symptoms, improved thermoregulation. A smaller subset of posts describes VIP as affecting biomarker panels — movement in TGF-beta-1, C4a, or VIP serum levels on repeat testing — though the reliability of these claims is difficult to evaluate from forum posts without access to the underlying lab data.

The MCAS community's relationship with VIP is somewhat different in character. Mast cell forum discussions tend to come from people who are managing a highly individual and unpredictable condition, where the triggers and responses are idiosyncratic and the treatment ladder is often assembled from multiple medications and approaches. VIP appears in these communities not as a protocol step but as something that a small number of members have tried under the guidance of mast cell-knowledgeable physicians, often after reaching the limits of what standard antihistamine and mast cell stabilizer regimens could provide.

The reports from MCAS community members are more variable than those from CIRS community members, which is consistent with what the underlying condition would predict — MCAS is heterogeneous in its presentation and likely heterogeneous in its mechanisms. Some reports describe significant reductions in reactivity: fewer activation events, higher threshold for degranulation triggers, improved tolerance of foods and environments that previously triggered responses. Others describe little effect or worsening on initial introduction, sometimes attributed to the VIP preparation itself as a trigger. The community consensus — such as consensus exists in a condition as variable as MCAS — appears to be that VIP may be helpful for a subset of patients, that starting at very low doses and titrating slowly reduces adverse reactions, and that it is not a universal solution.

The long COVID communities have generated a more recent and less settled conversation about VIP. The immunological overlap between long COVID and both CIRS and MCAS has been discussed in these communities, with frequent references to research papers on elevated inflammatory cytokines, mast cell activation, autonomic dysfunction, and in some cases findings suggesting low circulating VIP in post-COVID populations. Several users in long COVID communities describe applying elements of the Shoemaker protocol to their post-COVID presentation, sometimes with physician guidance and sometimes self-directed — the latter being a pattern that warrants explicit acknowledgment of the associated risks. The long COVID VIP conversation is earlier and less developed than the CIRS conversation, reflects a less established protocol structure, and has a corresponding higher variance in reported experiences.

The cost conversation runs through all of these communities and deserves direct attention, because it is a real and significant feature of the VIP discussion. VIP is consistently identified as one of the more expensive compounded peptides — multiple posts describe monthly costs ranging from several hundred to over a thousand dollars depending on dose, concentration, and pharmacy, with most of these costs not covered by insurance. This creates a selection effect in who gets to try VIP and who therefore shows up in community discussions having tried it — people who can afford a lengthy trial of an expensive compounded peptide. This selection bias matters for interpreting community reports: the people reporting on VIP are not representative of the broader chronic illness population, and their positive experiences may partly reflect confounders related to the resources and sustained healthcare access that allowed them to reach this point in the protocol.

The sourcing conversation is related and worth noting. VIP requires pharmaceutical-grade compounding from a licensed compounding pharmacy, and the quality and consistency of compounded peptides varies across pharmacies. Several community threads discuss which compounding pharmacies members have had good or bad experiences with, reflecting a real and practical concern about quality control in the compounded peptide space. The community knowledge about sourcing represents genuinely useful harm reduction information, even if it cannot substitute for provider oversight.

There is a feature of chronic illness communities that anyone reading their reports should hold consciously: these are spaces where people who have experienced profound and often prolonged suffering are sharing what has helped them, and the act of sharing is not neutral. Reporting bias is real — people who have tried something and found it helpful are more likely to return to the forum and describe their experience than people for whom it made no difference. The most dramatic recoveries generate the most engagement. The gradual, partial improvements — or the non-responses — are underrepresented. This is not a criticism of the communities themselves; it is a structural feature of self-reported experiential data that exists in any uncontrolled observational context.

Holding that caveat clearly: what the VIP community reports do provide is something that clinical trials rarely capture in this depth — the texture of what it is like to try this compound within a specific clinical context, what the side effect experience actually looks like in people who are managing multiple other conditions simultaneously, what the implementation looks like in real practice rather than protocol, and what the range of responses looks like when it is not filtered through study inclusion criteria. That is genuinely useful context, even if it is not evidence in the clinical sense.

The consistent thread across the CIRS, MCAS, and long COVID communities is the experience of illness that falls between recognized diagnostic categories, is dismissed or inadequately treated in standard medical practice, and has required patients to become experts in their own biology in order to receive anything resembling adequate care. VIP appears in that context as one tool among many, used by a subset of these patients under provider guidance, with a range of reported experiences that span from transformative to unhelpful. What it does not yet have is the randomized controlled trial data that would situate those individual experiences within a rigorous evidence base — and until that evidence exists, the community conversation remains exactly what it is: conversation, not guidance.